Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Outcomes of Therapy of Monoclonal Gammopathy of Renal Significance (MGRS)

Divaya Bhutani, Rajshekhar Chakraborty, Suzanne Lentzsch, J Christine Ye, Samuel M. Rubinstein, Sascha Tuchman, Eben I Lichtman

Blood (2024) 144 (Supplement 1): 6895.

https://doi.org/10.1182/blood-2024-210587

Published: 2024

Journal Articles

A Phase III Randomized Trial for Frail Newly Diagnosed Multiple Myeloma Patients Comparing Bortezomib- Lenalidomide-Dexamethasone (VRd-Lite followed by Len maintenance) with Daratumumab-Lenalidomide- Dexamethasone (DRd followed by Len+/- Dara Maintenance): SWOG S2209

Sikander Ailawadhi, Antje Hoering, J Christine Ye, Brea Lipe, Thomas R. Chauncey, Krisstina Gowin, David Calverley, Sarah A. Holstein, Erica L. Campagnaro, Adam Rosenthal, Jack Aiello, Saad Z. Usmani, Vincent Rajkumar, Robert Z. Orlowski

Blood (2024) 144 (Supplement 1): 3381.3.

https://doi.org/10.1182/blood-2024-209626

Published: 2024

Journal Articles

Clearance of Circulating Multiple Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 4687.

https://doi.org/10.1182/blood-2024-209181

Published: 2024

Journal Articles

Prognostic Significance of TP53 Mutations in Lymphoplasmacytic Lymphoma

Anath Lionel, Sherif Seif, Xiaowen Sun, Lei Feng, Lorenzo Gensini, Bria Gabriel, Lauren S. Lewis, Hima Bansal, Melody R. Becnel, Mahmoud R. Gaballa, Hans C. Lee, Oren Pasvolsky, Krina K. Patel, J Christine Ye, Keyur P. Patel, Donna M. Weber, Robert Z. Orlowski, Sheeba K. Thomas

Blood (2024) 144 (Supplement 1): 3024.

https://doi.org/10.1182/blood-2024-211193

Published: 2024

Journal Articles

Characterization of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Using Single Cell Transcriptomic Analysis

Minghao Dang, Sherif Seif, Maria Jose Acevedo-Calado, Linghua Wang, Bria Gabriel, Lauren S. Lewis, Lorenzo Gensini, Hima Bansal, Melody R. Becnel, Mahmoud R. Gaballa, Hans C. Lee, Oren Pasvolsky, Krina K. Patel, Donna M. Weber, J Christine Ye, Robert Z. Orlowski, Sheeba K. Thomas

Blood (2024) 144 (Supplement 1): 1584.

https://doi.org/10.1182/blood-2024-208915

Published: 2024

Journal Articles

Multi-Omic Single-Cell Characterization of Paired and Serial Samples in Responding and Non-Responding Patients Receiving BCMA Bispecific Antibody Therapy for Multiple Myeloma

Minghao Dang, Hans C. Lee, Hima Bansal, Maria Jose Acevedo-Calado, Li Qin, Wei Tan, Luz Yurany Moreno Rueda, David Berrios, Oren Pasvolsky, Mahmoud R. Gaballa, Melody R. Becnel, J Christine Ye, Krina K. Patel, Pei Lin, Sheeba K. Thomas, Donna M. Weber, Linghua Wang, Robert Z. Orlowski

Blood (2024) 144 (Supplement 1): 3272.

https://doi.org/10.1182/blood-2024-210080

Published: 2024

Journal Articles

Outcomes of Patients with Multiple Myeloma with Deletion 1p Following Autologous Stem Cell Transplant

Blood (2024) 144 (Supplement 1): 3344.

https://doi.org/10.1182/blood-2024-203700

Published: 2024

Journal Articles

Impact of Ethnicity on Long Term Outcomes of High-Dose Chemotherapy and Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma

Blood (2024) 144 (Supplement 1): 5154.

https://doi.org/10.1182/blood-2024-203824

Published: 2024

Journal Articles

Unveiling Clinical Potential: Exploring Cytogenomic Aberrations through Optical Genomic Mapping in Multiple Myeloma

J Christine Ye, Guilin Tang, Oren Pasvolsky, Melody R. Becnel, Mahmoud R. Gaballa, Krina K. Patel, Hans C. Lee, Sheeba K. Thomas, Donna M. Weber, Pei Lin, Robert Z. Orlowski

Blood (2024) 144 (Supplement 1): 1971.

https://doi.org/10.1182/blood-2024-212346

Published: 2024

Journal Articles

Personalized Neoantigen Peptide Vaccine with or without Lenalidomide for Patients with Intermediate or High Risk Smoldering Multiple Myeloma (SMM) to Prevent Progression to Multiple Myeloma (MM)

Krina K. Patel, Elisabet E. Manasanch, Hans C. Lee, J Christine Ye, Sheeba K. Thomas, Donna M. Weber, Melody R. Becnel, Mahmoud R. Gaballa, Hima Bansal, Zuzana Berkova, Sattva S. Neelapu, Cara L Haymaker, Minghao Dang, Linghua Wang, Greg Lizee, Robert Z. Orlowski

Blood (2024) 144 (Supplement 1): 4737.

https://doi.org/10.1182/blood-2024-205663

Published: 2024

Journal Articles

Phase 2 Study Using Minimal Residual Disease-Driven Adaptive Strategy in Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based Therapy - First Report from the Maestro Trial

J Christine Ye, Philip Boonstra, Erica L. Campagnaro, Matthew Pianko, Andrew Kin, Larry D Anderson, Jr., Brea Lipe, Moshe Talpaz, Jeffrey A. Zonder

Blood (2024) 144 (Supplement 1): 3379.

https://doi.org/10.1182/blood-2024-209505

Published: 2024

Journal Articles

Health-Related Quality of Life (HRQoL) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1: Interim Assessment up to 36 Weeks of Treatment

Blood (2023) 142 (Supplement 1): 3359.

https://doi.org/10.1182/blood-2023-179170

Published: 2023

Journal Articles

Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study

Blood (2023) 142 (Supplement 1): 4746.

https://doi.org/10.1182/blood-2023-177968

Published: 2023

Journal Articles

Initial Results from a Phase 1/2 Dose Escalation and Expansion Study Evaluating MS-553, a Novel and Selective PKCβ Inhibitor, in Patients with CLL/SLL

James S. Blachly, Deborah M. Stephens, J Christine Ye, Nicole Lamanna, Nitin Jain, Michael Niesman, Kai Zhang, Jennifer A. Woyach

Blood (2022) 140 (Supplement 1): 2324–2325.

https://doi.org/10.1182/blood-2022-171203

Published: 2022

Journal Articles

The Mydrug Platform Trial: Efficacy and Safety of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Patients with Functionally High-Risk Multiple Myeloma

Shaji K Kumar, Craig C Hofmeister, Noa Biran, Gurbakhash Kaur, Jing Christine Ye, Jeffrey A. Zonder, Umar Syed, Jennifer Yesil, Karen Woolley, George Mulligan, Hearn J. Cho

Blood (2022) 140 (Supplement 1): 4434–4435.

https://doi.org/10.1182/blood-2022-163737

Published: 2022

Journal Articles

Subcutaneous Epcoritamab in Patients with Richter's Syndrome: Early Results from Phase 1b/2 Trial (EPCORE CLL-1)

Arnon P. Kater, J Christine Ye, Jose Sandoval-Sus, Mar Bellido, Jacob Haaber Christensen, Anthony R. Mato, Ann Janssens, Toshihiko Oki, Daniela Hoehn, Marcia Rios, Alexandra Kuznetsova, Rebecca Valentin, Herbert Eradat

Blood (2022) 140 (Supplement 1): 850–851.

https://doi.org/10.1182/blood-2022-158298

Published: 2022

Journal Articles

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

Leon Bernal-Mizrachi, Ajay K. Nooka, Leonard Heffner, Craig E. Cole, Ravi Vij, J Christine Ye, Craig C Hofmeister, John Rushton, Zhengjia Chen, Subir Goyal, Munevver Cinar, Sagar Lonial, Jonathan L. Kaufman

Blood (2022) 140 (Supplement 1): 7311–7312.

https://doi.org/10.1182/blood-2022-170062

Published: 2022

Journal Articles

Role of Aneuploidy in Transcriptional Regulation and Clinical Prognosis in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Christopher T Su, MD, Liying Chen, MS, Jason Chen, MD, Brian Parkin, MD, Avery Polk, Malathi Kandarpa, PhD, Craig E. Cole, MD, Erica Campagnaro, MD, Josh Vo, PhD, Dan Robinson, PhD, Yi-Mi Wu, PhD, Moshe Talpaz, MD, Jennifer Yesil, MSc, Daniel Auclair, P. Leif Bergsagel, MD, Arul Chinnaiyan, MDPhD, Veerabhadran Baladandayuthapani, PhD, J Christine Ye, MDMSc

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-134558

Published: 2020

Journal Articles

A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax in Patients with Chronic Lymphocytic Leukemia

Kerry A Rogers, MD, Lai Wei, PhD, Seema A. Bhat, MD, Dan Jones, MD PhD, Erlene K. Seymour, MD, Deborah M. Stephens, DO, J Christine Ye, MDMSc, John C. Byrd, MD, Jennifer Woyach, MD

Blood (2019) 134 (Supplement_1): 3049.

https://doi.org/10.1182/blood-2019-125360

Published: 2019

Journal Articles

Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma-Alone or in Combination with Rituximab

Stephen D. Smith, MD, Javier Munoz, MD MS, FACP, Don Stevens, MD, Sonali M. Smith, MD, Tatyana A. Feldman, MD, J Christine Ye, MDMSc, Sven de Vos, MD PhD, Brian T. Hess, MD, Carole B. Miller, MD, James L. Khatcheressian, MD, Matt R. Birrell, Janet M. Leeds, PhD, Gregory P. Coffey, PhD, Pamela B. Conley, PhD, Glenn C. Michelson, MD, John T. Curnutte, MD PhD, Paul A. Hamlin, MD

Blood (2019) 134 (Supplement_1): 3981.

https://doi.org/10.1182/blood-2019-124231

Published: 2019

NARROW

Outcomes of Therapy of Monoclonal Gammopathy of Renal Significance (MGRS)

A Phase III Randomized Trial for Frail Newly Diagnosed Multiple Myeloma Patients Comparing Bortezomib- Lenalidomide-Dexamethasone (VRd-Lite followed by Len maintenance) with Daratumumab-Lenalidomide- Dexamethasone (DRd followed by Len+/- Dara Maintenance): SWOG S2209

Clearance of Circulating Multiple Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

Prognostic Significance of TP53 Mutations in Lymphoplasmacytic Lymphoma

Characterization of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Using Single Cell Transcriptomic Analysis

Multi-Omic Single-Cell Characterization of Paired and Serial Samples in Responding and Non-Responding Patients Receiving BCMA Bispecific Antibody Therapy for Multiple Myeloma

Outcomes of Patients with Multiple Myeloma with Deletion 1p Following Autologous Stem Cell Transplant

Impact of Ethnicity on Long Term Outcomes of High-Dose Chemotherapy and Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma

Unveiling Clinical Potential: Exploring Cytogenomic Aberrations through Optical Genomic Mapping in Multiple Myeloma

Personalized Neoantigen Peptide Vaccine with or without Lenalidomide for Patients with Intermediate or High Risk Smoldering Multiple Myeloma (SMM) to Prevent Progression to Multiple Myeloma (MM)

Phase 2 Study Using Minimal Residual Disease-Driven Adaptive Strategy in Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based Therapy - First Report from the Maestro Trial

Health-Related Quality of Life (HRQoL) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1: Interim Assessment up to 36 Weeks of Treatment

Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study

Initial Results from a Phase 1/2 Dose Escalation and Expansion Study Evaluating MS-553, a Novel and Selective PKCβ Inhibitor, in Patients with CLL/SLL

The Mydrug Platform Trial: Efficacy and Safety of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Patients with Functionally High-Risk Multiple Myeloma

Subcutaneous Epcoritamab in Patients with Richter's Syndrome: Early Results from Phase 1b/2 Trial (EPCORE CLL-1)

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

Role of Aneuploidy in Transcriptional Regulation and Clinical Prognosis in Relapsed and/or Refractory Multiple Myeloma (RRMM)

A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax in Patients with Chronic Lymphocytic Leukemia

Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma-Alone or in Combination with Rituximab

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only